45000Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o1/07/96 \ \ Origin: Appendix 5 \ \ Amended o1/07/98, o1/09/99, o1/07/00, 30/09/01, 11/03/02, o1/01/03, 24/10/05, o1/08/12, o4/03/13$ 

Name of entity		
BUILDINGIQ, INC.		
ARBN		
605 422 160		

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

†Class of \*securities issued or to be issued

CHESS Depositary Interests (*CDIs*) (quoted) representing shares of common stock of the Company (unquoted) (*Shares*)

Number of \*securities issued or to be issued (if known) or maximum number which may be issued **10,742,235** CDIs (quoted) representing **10,742,235** Shares (unquoted) comprising:

- 8,650,753 CDIs (quoted) representing 8,650,753 Shares (unquoted) issued to CDI holders under a Securities Purchase Plan announced to ASX on 27 August 2019 which closed on 27 September 2019 (SPP Securities); and
- 2,091,482 CDIs (quoted) representing 2,091,482 Shares (unquoted) issued to a director under the Placement announced to ASX on 28 April 2019 and 25 June 2019 following shareholder approval obtained at a Special Meeting of Shareholders held on 27 September 2019 (*Director Placement Securities*).

#### **Unlisted Options**

A total of 45,000 unlisted options issued under the Company's 2012 Employee Incentive Plan lapsed In September 2019 due to employee departures.

<sup>+</sup> See chapter 19 for defined terms.

Principal of terms the 3 +securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

## CDIs

The CDIs will be on the same terms as the Company's existing CDIs.

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes.
If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
Issue price or consideration	o The SPP Securities − 8,650,753 CDIs were issued at a price of \$0.0364 per CDI; o The Director Placement Securities: 1,129,944 CDIs were issued under Tranche 1 of the Placement at an issue price of \$0.0354 and 961,538 CDIs were issued under Tranche 2 of the Placement at an issue price of \$0.0364
Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The SPP Securities and the Director Placement Securities were issued to raise capital to support BuildinglQ's greenfield business growth and working capital requirements.
Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
The date the security holder resolution under rule 7.1A was passed	28 March 2019
	in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment  Issue price or consideration  Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)  Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i  The date the security holder resolution under rule 7.1A was

<sup>+</sup> See chapter 19 for defined terms.

6c	Number of *securities issued without security holder approval under rule 7.1	NIL
6d	Number of *securities issued with security holder approval under rule 7.1A	NIL
бе	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	NIL
6f	Number of *securities issued under an exception in rule 7.2	<ol> <li>SPP Securities: 8,650,753 CDIs (quoted) representing 8,650,753 Shares (unquoted) issued under a Securities Purchase Plan (Listing Rule 7.2 Exception 15)</li> <li>Director Placement Securities: 2,091,482 CDIs (quoted) representing 2,091,482 Shares (unquoted) issued with the approval of shareholders under Listing Rule 10.11 (Listing Rule 7.2 Exception 14).</li> </ol>
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Not applicable
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1 – 46,317,165 Rule 7.1A 31,781,749

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### 7 <sup>+</sup>Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

4 October 2019			

8 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in section 2 if applicable)

Number	<sup>+</sup> Class
319,172,949 (assuming all issued Shares are held as CDIs)	CDIs

9 Number and <sup>+</sup>class of all <sup>+</sup>securities not quoted on ASX (*including* the <sup>+</sup>securities in section 2 if applicable)

Number	<sup>+</sup> Class
15,020,535	Unlisted Options
<b>Comprising:</b> 2,112,500	Options issued to the underwriter at IPO
6,046,243	Options issued to directors, executives and employees under the Company's 2012 Equity Incentive plan
2,287,264	Options with an exercise price of A\$0.0675 and an expiry date of 31 December 2020.
2,287,264	Options with an exercise price of A\$0.1125 and an expiry date of 31 December 2020.
2,287,264	Options with an exercise price of A\$0.1350 and an expiry date of 31 December 2020,

<sup>+</sup> See chapter 19 for defined terms.

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

No change. The Company does not expect to pay a dividend in the foreseeable future

## Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the <sup>+</sup> securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
25	If the issue is contingent on security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do security holders sell their entitlements <i>in full</i> through a broker?
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?

<sup>+</sup> See chapter 19 for defined terms.

32	of th	w do security holders dispose their entitlements (except by e through a broker)?		
33	<sup>+</sup> Issue	sue date		
		<b>Quotation of securities</b> ly complete this section if you are applying for quotation of securities.	es	
34		pe of *securities ek one)		
(a)	X	<sup>+</sup> Securities described in Part 1		
(b)		All other <sup>+</sup> securities		
		Example: restricted securities at the end of the escrowed period, partly paid employee incentive share securities when restriction ends, securities issued on securities		
Entities that have ticked box 34(a)				
Addi	tional	al securities forming a new class of securities		
Tick to docum		cate you are providing the information or		
35		If the *securities are *equity securities, the names of the additional *securities, and the number and percentage held by those holders	0	
36		If the *securities are *equity securities, a distribution so *securities setting out the number of holders in the cate 1 - 1,000 1,001 - 5,000		
		5,001 - 10,000 10,001 - 100,000 100,001 and over		
37		A copy of any trust deed for the additional *securities		

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Entitie	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the <sup>+</sup> securities rank equally in all respects from the <sup>+</sup> issue date with an existing <sup>+</sup> class of quoted <sup>+</sup> securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another <sup>+</sup> security, clearly identify that other <sup>+</sup> security)		
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)	Number	<sup>+</sup> Class

<sup>+</sup> See chapter 19 for defined terms.

## **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	. Date 4 October 2019
	(Company secretary)
Print name:	Lisa Jones

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

== == == ==

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figures capacity is calculated	ure from which the placement	
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	249,223,825 Shares (equivalent to 249,223,825 CDIs)	
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	8,650,753 CDIs issued under a Security Purchase Plan (LR 7.2 Exception 15)	
exception in rule 7.2	<b>2,091,482</b> CDIs issued with approval under LR 10.11 (LR7.2 Exception 14)	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	<b>57,851,430 CDIs</b> (ratified under LR 7.4 on 27 September 2019)	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period		
"A"	317,817,490	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	47,672,624	
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	693,050	
• Under an exception in rule 7.2	662,409	
• Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:         <ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> </ul> </li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	1,355,459	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	47,672,624	
Note: number must be same as shown in Step 2		
Subtract "C"	1,355,459	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	<b>46,317,165</b> [Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

# Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	317,817,490	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	31,781,749	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	NIL	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	NIL	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	31,781,749	
Note: number must be same as shown in Step 2		
Subtract "E"	NIL	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	31,781,749	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.